To investigate predictors of response, remission, low disease activity (LDA), damage and drug discontinuation in patients with systemic lupus erythematosus (SLE) treated with belimumab.
Early disease and low baseline damage predict response to belimumab in patients with systemic lupus erythematosus
Fasano, Serena;Ciccia, Francesco;
2020
Abstract
To investigate predictors of response, remission, low disease activity (LDA), damage and drug discontinuation in patients with systemic lupus erythematosus (SLE) treated with belimumab.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
